Literature DB >> 23817009

Mitochondrial membrane permeabilisation by amyloid aggregates and protection by polyphenols.

Angelique Camilleri1, Claire Zarb, Mario Caruana, Ulrike Ostermeier, Stephanie Ghio, Tobias Högen, Felix Schmidt, Armin Giese, Neville Vassallo.   

Abstract

Alzheimer's disease and Parkinson's disease are neurodegenerative disorders characterised by the misfolding of proteins into soluble prefibrillar aggregates. These aggregate complexes disrupt mitochondrial function, initiating a pathophysiological cascade leading to synaptic and neuronal degeneration. In order to explore the interaction of amyloid aggregates with mitochondrial membranes, we made use of two in vitro model systems, namely: (i) lipid vesicles with defined membrane compositions that mimic those of mitochondrial membranes, and (ii) respiring mitochondria isolated from neuronal SH-SY5Y cells. External application of soluble prefibrillar forms, but not monomers, of amyloid-beta (Aβ42 peptide), wild-type α-synuclein (α-syn), mutant α-syn (A30P and A53T) and tau-441 proteins induced a robust permeabilisation of mitochondrial-like vesicles, and triggered cytochrome c release (CCR) from isolated mitochondrial organelles. Importantly, the effect on mitochondria was shown to be dependent upon cardiolipin, an anionic phospholipid unique to mitochondria and a well-known key player in mitochondrial apoptosis. Pharmacological modulators of mitochondrial ion channels failed to inhibit CCR. Thus, we propose a generic mechanism of thrilling mitochondria in which soluble amyloid aggregates have the intrinsic capacity to permeabilise mitochondrial membranes, without the need of any other protein. Finally, six small-molecule compounds and black tea extract were tested for their ability to inhibit permeation of mitochondrial membranes by Aβ42, α-syn and tau aggregate complexes. We found that black tea extract and rosmarinic acid were the most potent mito-protectants, and may thus represent important drug leads to alleviate mitochondrial dysfunction in neurodegenerative diseases.
© 2013.

Entities:  

Keywords:  AD; Alpha-synuclein; Alzheimer's disease; Amyloid-beta; Aβ(42); CCR; CL; Cardiolipin; Cyto c; IM and IMM; Mitochondrial membrane; OGB-1; OM and OMM; Oregon Green® 488 BAPTA-1; PD; Parkinson's disease; Polyphenol; TX-100; Tau; Triton X-100; WT; amyloid-beta (1–42); cardiolipin; cytochrome c; cytochrome c release; inner mitochondrial membrane; outer mitochondrial membrane; wild-type; α-syn; α-synuclein

Mesh:

Substances:

Year:  2013        PMID: 23817009     DOI: 10.1016/j.bbamem.2013.06.026

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  44 in total

Review 1.  Impact of membrane curvature on amyloid aggregation.

Authors:  Mayu S Terakawa; Yuxi Lin; Misaki Kinoshita; Shingo Kanemura; Dai Itoh; Toshihiko Sugiki; Masaki Okumura; Ayyalusamy Ramamoorthy; Young-Ho Lee
Journal:  Biochim Biophys Acta Biomembr       Date:  2018-04-28       Impact factor: 3.747

2.  Enhanced mitochondrial inhibition by 3,4-dihydroxyphenyl-acetaldehyde (DOPAL)-oligomerized α-synuclein.

Authors:  Theodore A Sarafian; Amneh Yacoub; Anastasia Kunz; Burkan Aranki; Grigor Serobyan; Whitaker Cohn; Julian P Whitelegge; Joseph B Watson
Journal:  J Neurosci Res       Date:  2019-08-16       Impact factor: 4.164

3.  The Therapeutic Implications of Tea Polyphenols Against Dopamine (DA) Neuron Degeneration in Parkinson's Disease (PD).

Authors:  Zhi Dong Zhou; Shao Ping Xie; Wuan Ting Saw; Patrick Ghim Hoe Ho; Hongyan Wang; Zhou Lei; Zhao Yi; Eng King Tan
Journal:  Cells       Date:  2019-08-16       Impact factor: 6.600

Review 4.  Type 2 diabetes as a protein misfolding disease.

Authors:  Abhisek Mukherjee; Diego Morales-Scheihing; Peter C Butler; Claudio Soto
Journal:  Trends Mol Med       Date:  2015-05-18       Impact factor: 11.951

Review 5.  Cardiolipin in Central Nervous System Physiology and Pathology.

Authors:  Caitlin B Pointer; Andis Klegeris
Journal:  Cell Mol Neurobiol       Date:  2016-12-30       Impact factor: 5.046

6.  Mitochondrial dysfunction induced by a post-translationally modified amyloid linked to a familial mutation in an alternative model of neurodegeneration.

Authors:  Krysti Todd; Silvia Fossati; Jorge Ghiso; Agueda Rostagno
Journal:  Biochim Biophys Acta       Date:  2014-09-28

7.  Monitoring of single vesicle cytochrome-c release illuminates BAK as a novel target of Aβ oligomers.

Authors:  Daniel A Linseman
Journal:  Biophys J       Date:  2014-10-07       Impact factor: 4.033

8.  Beta-amyloid oligomers activate apoptotic BAK pore for cytochrome c release.

Authors:  Jaewook Kim; Yoosoo Yang; Seung Soo Song; Jung-Hyun Na; Kyoung Joon Oh; Cherlhyun Jeong; Yeon Gyu Yu; Yeon-Kyun Shin
Journal:  Biophys J       Date:  2014-10-07       Impact factor: 4.033

Review 9.  Current perspective of mitochondrial biology in Parkinson's disease.

Authors:  Navneet Ammal Kaidery; Bobby Thomas
Journal:  Neurochem Int       Date:  2018-03-14       Impact factor: 3.921

Review 10.  Interplay between α-synuclein amyloid formation and membrane structure.

Authors:  Emma I O'Leary; Jennifer C Lee
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2018-10-02       Impact factor: 3.036

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.